Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2014-09-24 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
验资报告
Audit Report / Information Classification · 95% confidence The document is titled as a "验资报告" which translates to "Capital Verification Report" or "Audit Report on Capital". It is issued by a certified public accounting firm and details the verification of the company's capital increase through a non-public issuance of shares. The report includes detailed financial figures about the registered capital, share issuance, and funds raised, along with the auditor's opinion and certification. It references regulatory approvals from the China Securities Regulatory Commission and provides a formal audit opinion on the capital increase. The document is not a full annual or interim report but a standalone audit report focused on capital verification. Therefore, it fits the category of an Audit Report / Information (AR). The document length is substantial and contains detailed audit content, not merely an announcement or certification letter, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2014-09-24 Chinese
北京市康达律师事务所关于公司非公开发行股票发行过程和发行对象合规性的见证法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the compliance of a company's non-public stock issuance process and the issuance objects. It references specific approvals, board meetings, shareholder meetings, regulatory approvals from the China Securities Regulatory Commission, and details about the issuance process and subscription amounts. The document is not a financial report, earnings release, or management discussion but a legal compliance opinion related to a capital raising event. It is not a brief announcement but a detailed legal opinion letter. This fits best under the category of Capital/Financing Update (CAP), as it relates to the company's fundraising and capital issuance activities.
2014-09-24 Chinese
关于签订募集资金三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a tripartite supervision agreement for raised funds by the company 普洛药业股份有限公司. It details the specifics of the fundraising, the accounts where the funds are held, and the supervisory responsibilities of involved parties. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is relatively short (2058 characters) and serves as a formal announcement about the management and supervision of the raised capital. This fits the category of Capital/Financing Update (CAP), as it relates to fundraising activities and capital management.
2014-09-23 Chinese
第六届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the sixth board meeting of the company 普洛药业股份有限公司 held on August 27, 2014. It includes voting results on several agenda items such as approval of the 2014 semi-annual report, general manager's work report, financial work report, and amendments to the R&D management system. The document is short (1199 characters) and primarily reports on board meeting decisions and approvals rather than providing detailed financial statements or comprehensive reports. It does not contain the full semi-annual report or detailed financial data but references where the full report can be found. This fits the category of Board/Management Information (MANG), which covers announcements of board decisions and management changes or approvals.
2014-08-28 Chinese
2014年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2014 Half-Year Report Summary' (半年度报告摘要) for the company 普洛药业股份有限公司. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and asset information. It also includes management discussion and analysis (MD&A) sections discussing business operations, investments, R&D, and internal controls. The document length is 7648 characters, which is substantial and contains actual financial data and analysis, not just an announcement or summary. The presence of half-year financial data and management discussion indicates this is an Interim / Quarterly Report. The document is not a full annual report (10-K), nor is it a short earnings release or a regulatory filing. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2014
2014-08-28 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion by the independent directors of 普洛药业股份有限公司 regarding the company's related party transactions and external guarantees as of June 30, 2014. It references regulatory notices from the China Securities Regulatory Commission and discusses compliance with laws and company bylaws. The document is short (625 characters) and focuses on a specific compliance and governance issue rather than presenting full financial data or audit results. It is not an annual report, audit report, or financial statement. It is a formal statement related to governance and regulatory compliance, which fits best under Regulatory Filings (RNS) as it does not contain full audit or financial report content, nor is it a simple announcement of a report publication. Therefore, the classification is Regulatory Filings (RNS).
2014-08-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.